^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ENV-201

    i
    Other names: ENV-201, ENV-ONC-201
    Company:
    Endeavor BioMed
    Drug class:
    ULK1 inhibitor, ULK2 inhibitor
    Related drugs:
    2years
    The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib (AACR-NCI-EORTC 2022)
    ENV-201-mediated ULK1 inhibition thus shows promise as both a single agent or in combination with a growth factor/RAS/MAPK pathway-targeting cancer treatment.
    Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C
    |
    Krazati (adagrasib) • ENV-201